H Dr. Levitt has >35 years of experience as a physician-scientist and pharmaceuticals development including leadership in development stage and global commercial biopharmaceuticals. He is a serial inventor with >25 issued patents and entrepreneur having created and/or led multiple biopharmaceutical companies. Dr. Levitt is founder of Onspira Therapeutics where he served as CSO and board member that was sold to Sumitomo in 2019. His experience also includes Director Medical Affairs, Commercial Operations, CSL Behring; Chief Executive Officer, President and board member of Genera Corporation (NASDAQ). He has served as Principal Investigator multiple competitive Awards including the DoD, NIH, Cystic Fibrosis and Coulter Foundations
A Professor and Emeritus Chair, Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine. Scientific Founder and Scientific Advisor of GenVecInc, OncorusInc, Coda Biotherapeutics. He is the founder and former president of the American Society for Gene and Cell Therapy. Founding Editor of the Nature Journal Gene Therapy. He was also former President of the Association of Microbiology and Immunology Chairs. He has received the prestigious Gene Therapy Pioneer Award and Paradigm Builder Lectureship.
Mr. Barone has >30 years of business development and commercial operations leadership for public and private biopharma companies. His extensive licensing and M&A experience includes numerous value creating transactions as-well-as providing in-house counsel services. Founding member of Reliant Pharmaceuticals, co-founder of Essential Pharmaceuticals and Onspira Therapeutics, all of which had successful exits. Prior to that, Mr. Barone worked in finance, marketing, legal and business development at Merck.
Ms. Laura Grablutz has >25 years of regulatory experience having worked on numerous successful drug applications and filings. She has held positions of increasing responsibility in worldwide regulatory affairs at Auxilium Pharmaceuticals, Genaera Corporation and Centocor/JNJ. She worked on numerous successful biologics, small molecule, drug-device and device combination products applications and filings. Her RA leadership encompassed from early development to post-marketing, Orphan drugs, CMC, labeling, advertising and promotional review.
Dr. Janice A. Phillips is a private consultant for biologics, vaccine, cell and gene therapy businesses. Prior to this, she held the positions of Head, Technical Operations for WindMIL Therapeutics; VP, Product Development for the biosimilars group at Dr. Reddy’s Laboratories, Inc; VP, Product Development and Executive Director, Manufacturing Sciences & Technology at Auxilium Pharmaceuticals, Inc.; Executive Director, Manufacturing Technology at Tengion, Inc.; and served in various capacities for Centocor/J&J with responsibility for the development, technology transfer and technical support of upstream operations used to manufacture biopharmaceuticals.
Mr. Rongen is a serial entrepreneur and R&D / Commercial Development leader with extensive experience across many therapeutic areas and functions. He founded and progressed Matinas BioPharma (omega-3 and lipid-crystal nano-particle drug delivery) into a public company (NYSE:MTNB); and he was integral to the development and commercialization of blockbuster products such as Humira® and Lovaza®.